Tirzepatide is a dual GLP-1/GIP, or glucose-inhibitory peptide, agonist approved for the treatment of diabetes and obesity in the USA and more recently in Australia. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.